Table 1 Outcomes of the PET-2-negative per-protocol population.
From: Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
Standard CMT (N = 328) | ABVD alone (N = 300) | |||
|---|---|---|---|---|
Follow-up (months) | ||||
For disease status | 65 (64–67) | 62 (58–64) | ||
For survival status | 67 (65–72) | 64 (62–69) | ||
Tumor events | ||||
Progression | 0 | 1 | (<1%) | |
Early relapse (within one year after treatment) | 2 | (1%) | 9 | (3%) |
Late relapse | 14 | (4%) | 24 | (8%) |
Any tumor event | 16 | (5%) | 34 | (11%) |
Second-line therapies | ||||
HDCT and ASCT | 8 | (2%) | 14 | (5%) |
DHAP or ICE without HDCT/ASCT | 2 | (1%) | 0 | |
Other chemotherapy with or without radiotherapy | 3 | (1%) | 7 | (2%) |
Radiotherapy only | 1 | (<1%) | 7 | (2%) |
Antibody therapy | 0 | 1 | (<1%) | |
Relapse, but no second-line therapy | 1 | (<1%) | 0 | |
Unknown second-line therapy | 1 | (<1%) | 5 | (2%) |
Causes of death | ||||
Hodgkin lymphoma | 1 | (<1%) | 0 | |
Second primary malignancya | 4 | (1%) | 0 | |
Cardiovascular disease | 1 | (<1%) | 1 | (<1%) |
Other disease (unspecified) | 0 | 1 | (<1%) | |
Accident | 0 | 1 | (<1%) | |
Unclear | 3 | (1%) | 0 | |
Any event | 9 | (3%) | 3 | (1%) |
Second primary malignancies | ||||
Acute myeloid leukemia or myelodysplastic syndrome | 0 | 1 | (<1%) | |
Non-Hodgkin lymphoma | 4 | (1%) | 1 | (<1%) |
Solid tumor | 13 | (4%) | 10 | (3%) |
Any event | 17 | (5%) | 12 | (4%) |
